Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

Novartis agreed to license Abogen Biosciences' early-stage autoimmune mRNA therapy for $575 million upfront and up to $7.2 billion in milestones, a deal valued at as much as $7.8 billion. The transaction is part of an accelerating push by global drugmakers to source Chinese biotech assets as major franchises approach patent expirations; ING forecasts China will account for roughly one-third of global pipeline molecules in 2026, up from 4% in 2014. Comparable recent deals include Novo Nordisk's potential $2.6 billion Hengrui partnership and GSK's up-to-$750 million acquisition of a Chimagen blood-cancer asset.

Analysis

The market implication is less about any single early-stage asset than a durable repricing of China-originated clinical platforms as a source of pipeline replacement. For NVS, the modest upfront payment limits near-term P&L exposure, but the headline contingent value signals that management is willing to pay for optionality after its internal pipeline credibility weakened. This should support NVS's revenue-duration multiple only if it converts into visible Phase II/III readouts; absent that, investors will increasingly view external BD as an admission that organic R&D productivity is insufficient.

SMMT is the most direct public-market read-through because its value is already disproportionately tied to a China-originated asset entering global development. AZN's combination work can validate both the clinical utility and commercial legitimacy of Chinese-discovered oncology drugs, potentially narrowing the discount applied to SMMT's probability-adjusted sales. Conversely, broader enthusiasm will raise acquisition and licensing prices, making NVS, NVO and GSK less likely to earn attractive returns on incremental deals; Big Pharma's bargaining power declines as competitive auctions replace bilateral licensing.

The near-term risk is that investors capitalize milestone headline values as if they were purchase consideration. Milestones are heavily back-end loaded and contingent on regulatory and sales thresholds; a licensing wave can inflate private Chinese biotech valuations without changing near-term earnings. Over 6-18 months, the more consequential second-order effect is pressure on Western venture-backed biotech: assets with undifferentiated mechanisms or slow enrollment may lose partnering scarcity value, while companies with validated China rights or cross-border development infrastructure gain it. The thesis fails if Chinese-originated programs show inferior reproducibility in multinational trials, face cross-border data/regulatory restrictions, or fail to secure US/EU approvals.

Key Decisions for Investors

• Maintain/establish a 3-6 month long SMMT versus short XBI pair, sized small given binary clinical risk. The catalyst is global combination-program expansion and validation of ivonescimab's role across tumor settings; exit if trial design, enrollment, or safety updates weaken the probability of registrational development. This expresses China-platform validation while hedging broad biotech beta.
• Treat NVS as a watch-list accumulation candidate rather than a deal-driven long. Add only after the next earnings release confirms core-growth guidance and management quantifies the pipeline bridge to major loss-of-exclusivity exposures; a further guidance cut or another late-stage setback would invalidate the multiple-support thesis over the next 1-3 months.
• Avoid chasing NVO on licensing headlines. A China-sourced oral incretin program is too early to offset near-term pricing, competition, and semaglutide-franchise uncertainty; revisit only when human efficacy, tolerability, and manufacturing-scale data establish differentiation versus Lilly and other oral incretin entrants.
• Screen US/EU small-cap biotech holdings for partnership-risk exposure over 6-18 months: reduce names whose principal value proposition is an unvalidated, non-differentiated asset awaiting a Big Pharma deal. Prefer companies with Phase II proof-of-concept, protected global rights, or demonstrated ability to run multinational trials, where China-originated competition is less substitutable.